Zach, Good analysis, thank you. I just wanted to pointed out the timelines for approval from that report (Page 10):
Authorisation process Just under half (14/30) of applications that eventually resulted in granting of a conditional marketing authorisation contained a proposal for this authorisation type in the initial submission from the applicant. In other cases the proposal for a conditional authorisation was made either during the initial assessment (14/30) or at the re-examination stage (2/30). This likely indicates a certain reluctance of applicants to proactively propose a conditional authorisation type already in the initial application.
Unsurprisingly, later consideration of conditional marketing authorisation was linked with longer total duration of the assessment procedure (including clock-stops). Average (mean) combined duration of assessment and clock-stops is presented in the figure below, while median duration showed similar differences (323, 407 and 483.5 days for initial application, assessment procedure and re-examination, respectively). The average assessment and clock-stop duration for all positive opinions in centralised procedure in 2015 was 202 and 131 days, respectively7. It has to be noted that only three conditional marketing authorisations were granted following accelerated assessment (Darzalex, Isentress, Tagrisso), and the combination of these two early access tools has been now encouraged in a revised CHMP guideline.
Thus, we will need to patient to see a conditional approval. There were exceptions, however. February/March 2019?
Yes, it was Chemist. What is your view, if there is approval, on the issue of market acceptance by the EU medical community, due to the limitations of the data that ADXS is using? Given the safety factor and the “last resort” nature of the treatment. And are results for other indications material to the question?